India · Delayed Price · Currency is INR Q-Line Biotech Statistics
Total Valuation
Q-Line Biotech has a market cap or net worth of INR 13.12 billion. The enterprise value is 14.61 billion.
| Market Cap | 13.12B |
| Enterprise Value | 14.61B |
Important Dates
The last earnings date was Wednesday, June 17, 2026.
| Earnings Date | Jun 17, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
Q-Line Biotech has 23.33 million shares outstanding. The number of shares has increased by 6.78% in one year.
| Current Share Class | 23.33M |
| Shares Outstanding | 23.33M |
| Shares Change (YoY) | +6.78% |
| Shares Change (QoQ) | n/a |
| Owned by Insiders (%) | 71.27% |
| Owned by Institutions (%) | n/a |
| Float | 6.47M |
Valuation Ratios
The trailing PE ratio is 16.17.
| PE Ratio | 16.17 |
| Forward PE | n/a |
| PS Ratio | 3.78 |
| PB Ratio | 5.33 |
| P/TBV Ratio | 5.99 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | 80.15 |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | 26.23 |
| EV / Sales | 4.21 |
| EV / EBITDA | 14.09 |
| EV / EBIT | 15.72 |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 1.64, with a Debt / Equity ratio of 0.92.
| Current Ratio | 1.64 |
| Quick Ratio | 0.96 |
| Debt / Equity | 0.92 |
| Debt / EBITDA | 2.17 |
| Debt / FCF | -11.54 |
| Interest Coverage | 4.79 |
Financial Efficiency
Return on equity (ROE) is 25.55% and return on invested capital (ROIC) is 20.27%.
| Return on Equity (ROE) | 25.55% |
| Return on Assets (ROA) | 11.46% |
| Return on Invested Capital (ROIC) | 20.27% |
| Return on Capital Employed (ROCE) | 26.65% |
| Weighted Average Cost of Capital (WACC) | n/a |
| Revenue Per Employee | 11.10M |
| Profits Per Employee | 1.78M |
| Employee Count | 313 |
| Asset Turnover | 0.69 |
| Inventory Turnover | 1.45 |
Taxes
In the past 12 months, Q-Line Biotech has paid 168.28 million in taxes.
| Income Tax | 168.28M |
| Effective Tax Rate | 23.20% |
Stock Price Statistics
| Beta (5Y) | n/a |
| 52-Week Price Change | n/a |
| 50-Day Moving Average | n/a |
| 200-Day Moving Average | n/a |
| Relative Strength Index (RSI) | 80.46 |
| Average Volume (20 Days) | 409,244 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, Q-Line Biotech had revenue of INR 3.47 billion and earned 557.22 million in profits. Earnings per share was 34.79.
| Revenue | 3.47B |
| Gross Profit | 2.13B |
| Operating Income | 929.58M |
| Pretax Income | 725.50M |
| Net Income | 557.22M |
| EBITDA | 1.04B |
| EBIT | 929.58M |
| Earnings Per Share (EPS) | 34.79 |
Balance Sheet
The company has 764.37 million in cash and 2.25 billion in debt, with a net cash position of -1.49 billion or -63.89 per share.
| Cash & Cash Equivalents | 764.37M |
| Total Debt | 2.25B |
| Net Cash | -1.49B |
| Net Cash Per Share | -63.89 |
| Equity (Book Value) | 2.46B |
| Book Value Per Share | 166.06 |
| Working Capital | 1.34B |
Cash Flow
In the last 12 months, operating cash flow was 163.76 million and capital expenditures -359.14 million, giving a free cash flow of -195.38 million.
| Operating Cash Flow | 163.76M |
| Capital Expenditures | -359.14M |
| Depreciation & Amortization | 107.91M |
| Net Borrowing | 605.33M |
| Free Cash Flow | -195.38M |
| FCF Per Share | -8.38 |
Margins
Gross margin is 61.40%, with operating and profit margins of 26.76% and 16.04%.
| Gross Margin | 61.40% |
| Operating Margin | 26.76% |
| Pretax Margin | 20.88% |
| Profit Margin | 16.04% |
| EBITDA Margin | 29.86% |
| EBIT Margin | 26.76% |
| FCF Margin | n/a |
Dividends & Yields
Q-Line Biotech does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -6.78% |
| Shareholder Yield | -6.78% |
| Earnings Yield | 4.25% |
| FCF Yield | -1.49% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | |
| Graham Upside |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
| Altman Z-Score | n/a |
| Piotroski F-Score | 4 |